The Federal State Unitary Enterprise Moscow Endocrine Plant (hereinafter as the Enterprise), which is under jurisdiction of the Ministry of Industry and Trade of Russia pursuant to the commitment of the Russian Federation Government on the import of medicinal products unregistered in the Russian Federation, based on the necessity provided by the Ministry of Health of the Russian Federation Healthcare, signed contracts with foreign manufacturers for supply of the required dosage forms from France, Great Britain, Germany, Belgium, Spain and Latvia.
Commercial agencies of the Russian Federation in China, France and Germany have been involved in the organisation of work.
By November 11, 2019, the Enterprise imported in full 7620 clobazam packs (trade name - Urbanil) in solid dosage forms - capsules 5 g No. 30 and tablets 10 mg No. 30.
Apart from the import of the required medicinal products to the Russian Federation, the work has been organised together with the Ministry of Health of Russia with regional healthcare bodies on the shipment of psychotropic medications to the subjects of the Russian Federation.
Donation (assignation) agreements were concluded with 69 subjects of the Russian Federation that notified about the necessity in dosage forms unregistered in the Russian Federation. The product Clobazam will be shipped in full by November 13, 2019 to the following subjects of the Russian Federation: the Altai Territory, the Amur Region, the Astrakhan Region, the Vladimir Region, the Volgograd Region, the Vologda Region, the Voronezh Region, the Jewish Autonomous Region, the Ivanovo Region, the Kabardino-Balkarian Republic, the Kaliningrad Region, the Kaluga Region, the Kamchatka Region, the Kemerovo Region, the Kirov Region, the Kostroma Region, the Krasnodar Territory, the Kursk Region, the Leningrad Region, the Lipetsk Region, Moscow, the Moscow Region, the Nizhny Novgorod Region, the Novosibirsk Region, the Omsk Region, the Orenburg Region, the Oryol Region, the Perm Krai, the Pskov Region, the Republic of Buryatia, the Republic of Dagestan, the Republic of Ingushetia, the Republic of Karelia, the Komi Republic, the Republic of Mordovia, the Republic of Tatarstan, the Republic of Udmurtia, the Republic of Yakutia, the Rostov Region, the Ryazan Region, the Samara Region, St. Petersburg, the Saratov Region, the Sakhalin Region, the Sverdlovsk Region, the Smolensk Region, Stavropol Territory, the Tambov Region, the Tver Region, the Tomsk region, the Tula Region, the Tyumen Region, Khabarovsk Territory, the Chelyabinsk Region, the Chechen Republic, the Chuvash Republic, Yamalo-Nenets Autonomous Okrug, and the Yaroslavl Region.
As part of the organisation of imported medicinal products own production, the Ministry of Industry and Trade of Russia together with the Enterprise has introduced medicinal products "Diazepam, solution for rectal administration, 2,5 mg/1,25 ml, 5 mg/2,5 ml, 10 mg/2,5 ml, 20 mg/5 ml”, “Midazolam, solution for oromucosal (buccal) use in doses of 2,5 mg/ml, 5 mg/ml, 7,5 mg/ml, 10 mg/ml”. The approximate term of start of production is QIV, 2020. Moreover, the introduction of own-produced “Clobazam, 10 mg tablets” has been organised. The approximate term of start of production is the year of 2021.
Comment type is not specified in the component properties.